Interleukin 2 Therapy in Cancer: Identifying Responders
Author Information
Author(s): J. Broom, S.D. Heys, P.H. Whiting, K.G.M. Park, A. Strachan, I. Rothnie, C.R. Franks, O. Eremin
Primary Institution: University of Aberdeen
Hypothesis
Can C-reactive protein (CRP) levels predict which cancer patients will respond to interleukin 2 therapy?
Conclusion
CRP levels can help predict which cancer patients are likely to respond to interleukin 2 therapy.
Supporting Evidence
- Responders had significantly lower baseline CRP levels compared to non-responders.
- The CRP stimulation index was much higher in responders during treatment.
- Six patients responded to rIL2 therapy, while nine did not.
Takeaway
Doctors can look at a protein called CRP in the blood to see if cancer patients might get better with a specific treatment.
Methodology
Fifteen patients with metastatic colorectal cancer were treated with rIL2 and CRP levels were measured before and during treatment.
Limitations
The study had a small sample size and focused only on one type of cancer.
Participant Demographics
Fifteen patients with metastatic colorectal carcinoma, including both males and females.
Statistical Information
P-Value
0.004
Statistical Significance
p=0.004
Want to read the original?
Access the complete publication on the publisher's website